The First Coffee & Coaching Session by Women in Preventive Cardiology (WIPC) Working Group: Disney Creative Thinking Strategy

By ASPC | May 17, 2022

The Women in Preventive Cardiology (WIPC) working group had our first formal meeting in January 2021 with the purpose “to support and mentor women in preventive cardiology and to advocate for women’s cardiovascular health by promoting optimal treatment and transdisciplinary research to improve women’s cardiovascular outcomes.” To achieve this goal, the WIPC presented the first…

Read More

ASPC Announces Official Program Covering the ABCs of Preventive Cardiology at Premier Annual Congress on CVD Prevention

By ASPC | May 2, 2022

JACKSONVILLE, Fla. – The American Society for Preventive Cardiology (ASPC) announces the official program for the ASPC 2022 Congress on CVD Prevention, scheduled July 29-31, 2022 in Louisville, KY. The program covers the “ABCs of Preventive Cardiology” over the 2.5 day live, in-person program, and can be found on aspconline.org/2022congress. Included in the 2022 program…

Read More

Jardiance® phase III EMPA-KIDNEY trial will stop early due to clear positive efficacy in people with chronic kidney disease

By ASPC | March 17, 2022

OXFORD, United Kingdom and RIDGEFIELD, Conn. and INDIANAPOLIS, March 16, 2022 /PRNewswire/ — The EMPA-KIDNEY trial, evaluating the effect of Jardiance® (empagliflozin) in adults with chronic kidney disease (CKD), will stop early based on a recommendation from the trial’s Independent Data Monitoring Committee. This follows a formal interim assessment that met prespecified criteria for positive efficacy, announced the Medical Research Council (MRC) Population…

Read More

REGENERON AND ULTRAGENYX COLLABORATE TO COMMERCIALIZE EVKEEZA® (EVINACUMAB) OUTSIDE THE UNITED STATES

By ASPC | January 11, 2022

Evkeeza is a first-in-class medicine approved by the U.S. Food and Drug Administration (FDA) and European Commission (EC) to treat an ultra-rare inherited form of high cholesterol TARRYTOWN, N.Y. and NOVATO, Calif., Jan. 7, 2022 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Ultragenyx Pharmaceutical Inc. today announced a license and collaboration agreement for Ultragenyx to clinically develop, commercialize and distribute Evkeeza® (evinacumab)…

Read More

FDA Approval of LEQVIO(R) (inclisiran)

By ASPC | January 7, 2022

Novartis has announced that LEQVIO® (inclisiran) has been approved by the FDA for patients with atherosclerotic cardiovascular disease (ASCVD) who need to further lower their bad cholesterol, despite being on a maximally tolerated statin. If interested, the LEQVIO full prescribing information can be found here: https://www.novartis.us/sites/www.novartis.us/files/leqvio.pdf Novartis is committed to continuing their work with the…

Read More

Finding a Job as a Preventive Cardiologist

By ASPC | October 5, 2021

by Charles German, MD, MS and Nicole Harkin, MD Increasing rates of sedentary behavior and low levels of physical activity, coupled with the rise in cardiometabolic diseases, have highlighted a critical need for atherosclerotic cardiovascular disease prevention, and preventive cardiologists are at the forefront of this public health crisis. However, few trainees receive adequate exposure…

Read More